Patents by Inventor Bridget M. Cole

Bridget M. Cole has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phthalazinone compounds and methods for the treatment of cystic fibrosis
    Patent number: 9682969
    Abstract: The invention relates to a compound of Formula I and methods of treating CFTR (cystic fibrosis transmembrane conductance regulator) mediated diseases, in particular cystic fibrosis, comprising the step of administering a therapeutically effective amount of a compound of Formula I to a patient in need thereof:
    Type: Grant
    Filed: January 19, 2015
    Date of Patent: June 20, 2017
    Assignee: Flatley Discovery Lab, LLC
    Inventor: Bridget M. Cole
  • Triazolopyridine compounds and methods for the treatment of cystic fibrosis
    Patent number: 9573948
    Abstract: The invention relates to a compound of Formula I or IA and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof:
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: February 21, 2017
    Assignee: Flatley Discovery Lab
    Inventors: Bridget M. Cole, Richard A. Nugent, Paul T. Smith, Jr.
  • ISOXAZOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20160128984
    Abstract: The invention relates to a compound of Formula I and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I or II to a patient in need thereof:
    Type: Application
    Filed: October 2, 2015
    Publication date: May 12, 2016
    Inventors: Bridget M. Cole, Andrew Kolodziej
  • TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20160096835
    Abstract: The invention relates to a compound of Formula I or IA and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof:
    Type: Application
    Filed: October 6, 2015
    Publication date: April 7, 2016
    Inventors: Bridget M. Cole, Richard A. Nugent, Paul T. Smith, JR.
  • PHTHALAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20150299176
    Abstract: The invention relates to a compound of Formula I and methods of treating CFTR (cystic fibrosis transmembrane conductance regulator) mediated diseases, in particular cystic fibrosis, comprising the step of administering a therapeutically effective amount of a compound of Formula I to a patient in need thereof:
    Type: Application
    Filed: January 19, 2015
    Publication date: October 22, 2015
    Inventor: Bridget M. Cole
  • Phthalazinone compounds and methods for the treatment of cystic fibrosis
    Patent number: 8937178
    Abstract: The invention relates to a compound of Formula I and methods of treating CFTR (cystic fibrosis transmembrane conductance regulator) mediated diseases, in particular cystic fibrosis, comprising the step of administering a therapeutically effective amount of a compound of Formula I to a patient in need thereof:
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: January 20, 2015
    Assignee: Flatley Discovery Lab
    Inventor: Bridget M. Cole
  • PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20150005300
    Abstract: The invention relates to a compound of having the following formulae and methods of treating cystic fibrosis:
    Type: Application
    Filed: March 13, 2014
    Publication date: January 1, 2015
    Applicant: FLATLEY DISCOVERY LAB
    Inventors: BRIDGET M. COLE, RICHARD A. NUGENT, ANDREW KOLODZIEJ, KAREN HANDLEY, YEVGEN BARSUKOV
  • COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20140371263
    Abstract: The invention relates to a compound of Formula I and methods of treating CFTR (cystic fibrosis transmembrane conductance regulator) mediated diseases, in particular cystic fibrosis, comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof:
    Type: Application
    Filed: March 13, 2014
    Publication date: December 18, 2014
    Applicant: FLATLEY DISCOVERY LAB
    Inventors: Michael P. Zawistoski, Yevgen Barsukov, Bridget M. Cole, Richard A. Nugent
  • COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20140371238
    Abstract: The invention relates to a compound of Formula I and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof:
    Type: Application
    Filed: March 13, 2014
    Publication date: December 18, 2014
    Applicant: FLATLEY DISCOVERY LAB
    Inventors: Michael P. Zawistoski, Yevgen Barsukov, Bridget M. Cole, Richard A. Nugent
  • PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20140371225
    Abstract: The invention relates to a compound of Formula I and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I to a patient in need thereof:
    Type: Application
    Filed: March 13, 2014
    Publication date: December 18, 2014
    Applicant: FLATLEY DISCOVERY LAB
    Inventors: Bridget M. Cole, Richard A. Nugent, Andrew Kolodziej, Karen Handley, Yevgen Barsukov
  • PHTHALAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20140274933
    Abstract: The invention relates to a compound of Formula I and methods of treating CFTR (cystic fibrosis transmembrane conductance regulator) mediated diseases, in particular cystic fibrosis, comprising the step of administering a therapeutically effective amount of a compound of Formula I to a patient in need thereof:
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: FLATLEY DISCOVERY LAB
    Inventor: Bridget M. Cole
  • Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
    Publication number: 20040157834
    Abstract: Compounds according to the formula A-Z-W as herein described, wherein A is selected from the groups consisting of: A′-(CH2)n—, A′-(CH2)nSO2—, and A′-(CH2)nCO—, where n is 0 to 4; and A═ is selected from
    Type: Application
    Filed: February 9, 2004
    Publication date: August 12, 2004
    Applicant: Pfizer Inc
    Inventors: Bruce A. Hay, Bridget M. Cole, Anthony P. Ricketts
  • Microsomal triglyceride transfer protein inhibitor
    Publication number: 20040132745
    Abstract: The present invention provides inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion having Formula (I) which are useful for the treatment of obesity and related diseases, as well as prevention and treatment of atherosclerosis and its clinical sequelae, for lowering serum lipids, and in the prevention and treatment of related diseases. The invention further relates to pharmaceutical compositions comprising the compounds of the present invention and to methods of treating obesity, atherosclerosis, and related diseases and/or conditions with the compounds of the present invention, either alone or in combination with other medicaments, including lipid-lowering agents.
    Type: Application
    Filed: December 19, 2003
    Publication date: July 8, 2004
    Applicant: Pfizer Inc
    Inventors: Peter Bertinato, Brian S. Bronk, Henry Cheng, George Chang, Bridget M. Cole, Jin Li, Roger B. Ruggeri
  • Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
    Patent number: 6720330
    Abstract: Compounds according to the formula A—Z—W as herein described, wherein A is selected from the groups consisting of: A′—(CH2)n—, A′—(CH2)nSO2—, and A′—(CH2)nCO—, where n is 0 to 4; and A′ is selected from (a) (C6-C10)aryl-, or (b) (C1-C9)heteroaryl-; which groups may be optionally substituted; and pharmaceutically acceptable salts, solvates or hydrates thereof; pharmaceutical compositions thereof; and methods useful to facilitate secretion of growth hormone(GH) in mammals.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: April 13, 2004
    Assignee: Pfizer Inc.
    Inventors: Bruce A. Hay, Bridget M. Cole, Anthony P. Ricketts
  • Somatostatin antagonists and agonists that act at the sst subtype 2 receptor
    Publication number: 20040058877
    Abstract: Compounds according to the formula: 1
    Type: Application
    Filed: September 8, 2003
    Publication date: March 25, 2004
    Applicant: Pfizer Inc
    Inventors: Bruce A. Hay, Anthony P. Ricketts, Bridget M. Cole
  • Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
    Patent number: 6696418
    Abstract: Compounds according to the formula: and pharmaceutically acceptable salts, solvates or hydrates thereof; wherein group Ar is optionally substituted (C6-C10)aryl or (C1-C9)heteroaryl; X is a direct link, —CH2—, —SO2—, —CO—, —CHR1— where R1 is (C1-C6) alkyl, or —CR1′R1″— where both R1′ and R1″ are, independently, (C1-C6)alkyl; Y is N or CH; and Z and W are as herein defined, and pharmaceutical compositions thereof, and methods useful to facilitate secretion of growth hormone(GH) in mammals.
    Type: Grant
    Filed: July 17, 2000
    Date of Patent: February 24, 2004
    Assignee: Pfizer Inc.
    Inventors: Bruce A. Hay, Anthony P. Ricketts, Bridget M. Cole
  • Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
    Patent number: 6495589
    Abstract: Compounds according formula (I) A—G—Z—W and pharmaceutically acceptable salts, solvates or hydrates thereof; wherein, A is (C6-C10)aryl, (C6-C10)aryl-SO2, (C6-C10)aryl-CH2—, (C6-C10)arylcarbonyl, (C1-C9)heteroaryl, (C1-C9)heteroaryl-SO2—, (C1-C9)heteroaryl-CH2—; or (C1-C9)heteroarylcarbonyl; G is selected from the group consisting of:  where B is (C6-C10)aryl or (C1-C9)heteroaryl, and X is CH2, SO2, or carbonyl;  where X is CH2, SO2, or carbonyl; and R1 and R1′ are each independently selected from H, CN, (C1-C8)alkyl-, and phenyl(CH2)—, wherein said alkyl and phenyl groups are optionally substituted; and  where Z and W are as defined in the present Specificiation; and pharmaceutical compositions and methods useful to increase secretion of growth hormone(GH) from the anterior pituitary of mammals, including on a sustained release basis.
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: December 17, 2002
    Assignee: Pfizer Inc.
    Inventors: Bruce A. Hay, Bridget M. Cole, Anthony P. Ricketts
  • Somatostatin antagonists and agonists that act at the sst subtype 2 receptor
    Publication number: 20020128206
    Abstract: Compounds according to the formula: 1
    Type: Application
    Filed: March 7, 2002
    Publication date: September 12, 2002
    Inventors: Bruce A. Hay, Anthony P. Ricketts, Bridget M. Cole
  • Somatostatin antagonists and agonists
    Publication number: 20020091090
    Abstract: Compounds according to the formula A-B-Z-W, wherein
    Type: Application
    Filed: September 14, 2001
    Publication date: July 11, 2002
    Inventors: Bridget M. Cole, Anthony P. Ricketts, Bruce A. Hay
  • Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
    Publication number: 20020091125
    Abstract: Compounds according to the formula A-Z-W as herein described, wherein A is selected from the groups consisting of: A′—(CH2)n—, A′—(CH2)nSO2—, and A′—(CH2)nCO—, where n is 0 to 4; and A′ is selected from
    Type: Application
    Filed: September 17, 2001
    Publication date: July 11, 2002
    Inventors: Bruce A. Hay, Bridget M. Cole, Anthony P. Ricketts